Key Highlights

  • Phase 2 Part C data show 90.5% interim disease control rate
  • Combination of ateganosine followed by cemiplimab tested in third-line NSCLC
  • Shares dipped nearly 2% to $662.88 despite positive readout
  • Result adds to Regeneron's oncology combination portfolio
  • Data reflects growing focus on sequential immunotherapy strategies

Regeneron Pharmaceuticals Inc. disclosed positive initial efficacy data from Part C of its Phase 2 expansion trial evaluating ateganosine (THIO-101) followed by cemiplimab in patients with third-line advanced non-small cell lung cancer, reporting an interim disease control rate of 90.5%. The result adds a meaningful data point to Regeneron's broader strategy of building combination and sequential immunotherapy regimens around cemiplimab, its approved PD-1 inhibitor already marketed under the Libtayo brand for multiple oncology indications.

Third-line NSCLC represents a particularly challenging treatment setting, as patients at this stage have typically already progressed through both chemotherapy and first-line immunotherapy or targeted treatment, leaving oncologists with a narrowing set of options and generally more modest expectations for disease control relative to earlier treatment lines. A 90.5% disease control rate in this population — even as an interim readout — represents a notably high bar relative to typical outcomes for third-line NSCLC therapies, though the figure alone does not fully characterize depth or durability of benefit.

The sequencing strategy itself is scientifically notable: ateganosine, a telomerase-targeted agent, is administered ahead of cemiplimab rather than in simultaneous combination, a design intended to potentially prime the tumor microenvironment or immune response before checkpoint inhibition is introduced. If validated in larger studies, sequential regimens of this kind could offer a template applicable beyond NSCLC to other tumor types where checkpoint inhibitor monotherapy has plateaued in efficacy.

Despite the encouraging data, Regeneron shares dipped nearly 2% to $662.88, a decline likely attributable to broader market conditions or profit-taking rather than the trial result itself, given the company's scale — a $69.5 billion market capitalization means any single trial readout, however positive, typically has limited standalone influence on the stock's day-to-day movement.

What did the Phase 2 NSCLC trial data show?

Part C of the trial reported an interim disease control rate of 90.5% for ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer patients.

Why is the sequencing of ateganosine before cemiplimab significant?

The design is intended to potentially prime the tumor microenvironment ahead of checkpoint inhibition, a strategy that could inform combination approaches beyond NSCLC if validated further.

This article is for informational purposes and does not constitute investment advice.